Inflammatory bowel disease (IBD) presents a significant healthcare challenge, affecting millions worldwide with its chronic inflammation of the gastrointestinal tract. Current treatments, mainly systemic immunosuppressants, have limited efficacy and cause various side effects. This project proposes an innovative solution: an engineered probiotic that detects and treats inflammation locally within the GI tract. The first objective involves modifying E. coli to detect inflammation by utilizing calprotectin, a standard biomarker for IBD activity. A biosensor will be made with the bacterial promoter, ykgMO-IGS, responsive to calprotectin, triggering the production of a green fluorescent reporter protein, and allowing noninvasive monitoring of disease activity. Upon inflammation detection, the next step involves targeted therapy using the anti-inflammatory cytokine Interleukin 10 (IL-10). By coupling IL-10 transcription to the calprotectin-responsive promoter, the engineered probiotic will produce IL-10 locally in response to inflammation. We propose a secretory pathway that delivers IL-10 outside of the E. coli while maintaining its structure and functionality. We also propose an environment-dependent kill switch that activates if the bacteria leaves the gut to ensure IL-10 localization and long-term effectiveness of the engineered E. coli system.